Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 685-696

  Löschmann, Nadine ^a   Michaelis, Martin ^b   Rothweiler, Florian ^a   Zehner, Richard ^a   Cinatl, Jaroslav ^a   Voges, Yvonne ^a   Sharifi, Mohsen ^c   Riecken, Kristoffer ^d   Meyer, Jochen ^e   von Deimling, Andreas ^e   Fichtner, Iduna ^f   Ghafourian, Taravat ^c   Westermann, Frank ^g   Cinatl Jr , Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF KENT   (United Kingdom)

^c MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE 7 INHIBITOR; CYCLIN DEPENDENT KINASE 9 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN 1; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL] ISONIPECOTAMIDE; NAVELBINE; PACLITAXEL; PROTEIN BAX; PROTEIN P21; PROTEIN P53; RHODAMINE 123; TOPOTECAN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DEATH; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RNA INTERFERENCE; RNA SYNTHESIS; SYSTEMIC ACQUIRED RESISTANCE; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84891682776     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13544     Document Type: Article

References (49)

1. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, et al. (2004). N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[5-(1, 1-dimethylethyl)-2-oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47, 1719-1728.
2. Mukhopadhyay P, Ali MA, Nandi A, Carreon P, Choy H, and Saha D (2006). The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1β-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells. Cancer Res 66, 1758-1766.
3. Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J, Bentley C, Cansfield AD, Jackson PS, Lockie AM, et al. (2008). Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 7, 3898-3907.
4. Ali MA, Choy H, Habib AA, and Saha D (2007). SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9, 370-381.
5. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, and Plunkett W (2009). Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113, 4637-4645.
6. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, and Hawtin RE (2009). SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 64, 723-732.
7. Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, and Plunkett W (2010). Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 70, 6587-6597.
8. Kruse U, Pallasch CP, Bantscheff M, Eberhard D, Frenzel L, Ghidelli S, Maier SK, Werner T, Wendtner CM, and Drewes G (2011). Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89-100.
9. Walsby E, Lazenby M, Pepper C, and Burnett AK (2011). The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25, 411-419.
10. Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, Yeung SC, and Pan J (2012). Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 plateletderived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res 18, 1966-1978.
11. Boquoi A, Chen T, and Enders GH (2009). Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. Cancer Prev Res (Phila) 2, 800-806.
12. Heath EI, Bible K, Martell RE, Adelman DC, and Lorusso PM (2008). A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26, 59-65.
13. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, et al. (2010). Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28, 3015-3022.
14. Robak P and Robak T (2012). A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Curr Med Chem 19, 5294-5318.
15. Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, Endicott JA, Douc-Rasy S, Bénard J, Oumata N, et al. (2010). CDK inhibitors roscovitine and CR8 triggerMcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 1, 369-380.
16. Garrofé-Ochoa X, Cosialls AM, Ribas J, Gil J, and Boix J (2011). Transcriptional modulation of apoptosis regulators by roscovitine and related compounds. Apoptosis 16, 660-670.
17. Maris JM (2010). Recent advances in neuroblastoma. N Engl J Med 362, 2202-2211.
18. Brodeur GM (2011). Knowing your ABCCs: novel functions of ABCC transporters. J Natl Cancer Inst 103, 1207-1208.
19. Chen L and Tweddle DA (2012). p53, SKP2, and DKK3 as MYCN target genes and their potential therapeutic significance. Front Oncol 2, 173.
20. Cinatl J Jr, Vogel JU, Cinatl J, Weber B, Rabenau H, Novak M, Kornhuber B, and Doerr HW (1996). Long-term productive human cytomegalovirus infection of a human neuroblastoma cell line. Int J Cancer 65, 90-96.
21. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, and Cinatl J Jr (2003). Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104, 36-43.
22. Kotchetkov R, Driever PH, Cinatl J, Michaelis M, Karaskova J, Blaheta R, Squire JA, Von Deimling A, Moog J, and Cinatl J Jr (2005). Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 27, 1029-1037.
23. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, Breitling R, Mayer B, Deubzer H, Witt O, Kreuter J, et al. (2010). Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 79, 130-136.
24. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling A, Rödel F, et al. (2011). Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2, e243.
25. Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, et al. (2010). Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12, 1023-1030.
26. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, and von Deimling A (1997). Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7, 871-875.
27. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, and Cinatl J Jr (2009). Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69, 416-421.
28. Aller S, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Qinghai Z, Urbatsch IL, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722.
29. Bikadi Z, Hazai I, Malik D, Jemnitz K, Veres Z, Hari P, Ni Z, Loo TW, Clarke DM, Hazai E, et al. (2011). Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS One 6, e25815.
30. Waterhouse NJ and Trapani JA (2003). A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ 10, 853-855.
31. Ozvegy-Laczka C, Cserepes J, Elkind NB, and Sarkadi B (2005). Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 8, 15-26.
32. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, et al. (2007). Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67, 11012-11020.
33. Kamath AV, Chong S, Chang M, and Marathe PH (2005). P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats. Cancer Chemother Pharmacol 55, 110-116.
34. Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, Löschmann N, von Deimling A, Breitling R, Doerr HW, Rödel F, et al. (2012). Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis 3, e294.
35. Yankulov KY and Bentley DL (1997). Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J 16, 1638-1646.
36. Peterlin BM and Price DH (2006). Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23, 297-305.
37. Sharma SV, Haber DA, and Settleman J (2010). Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10, 241-253.
38. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, and Norris MD (1997). The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 33, 2031-2036.
39. de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, et al. (2007). Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48, 311-317.
40. Pituch-Noworolska A, Zaremba M, and Wieczorek A (2009). Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 60, 168-173.
41. Dhooge CR, De Moerloose BM, Benoit YC, Van Roy N, Philippé J, and Laureys GG (1997). Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma. Cancer 80, 1250-1257.
42. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, et al. (2010). High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res 16, 1108-1118.
43. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, and Lunec J (2003). The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197, 93-98.
44. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, and Lunec J (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61, 8-13.
45. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, and Reynolds CP (2000). p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 35, 563-568.
46. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, and Reynolds CP (2001). Loss of p53 function confers highlevel multidrug resistance in neuroblastoma cell lines. Cancer Res 61, 6185-6193.
47. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, Danglot G, de Thé H, Bénard J, May E, et al. (2006). Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 34, 5603-5612.
48. Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, Gurova KV, Norris MD, and Gudkov AV (2007). p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 67, 10351-10360.
49. Krystof V, Baumli S, and Fürst R (2012). Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target. Curr Pharm Des 18, 2883-2890.